

## Xbrane Biopharma Q2 2023 - A setback but not case altering

Redeye considers Xbrane's Q2 weak due to slower sales ramp-up than anticipated and postponed profitability. We lower our fair value range but the drastic 43% drop observed yesterday reflects an excessively pessimistic and short-term perspective on the company.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Xbrane Biopharma Q2 2023 - A setback but not case altering](#)